Our data show that, even within the prognostic DNA methylation subtypes, patients harbouring non-R132H IDH1/2-mutated tumours had a significantly longer survival compared to those harbouring IDH1R132H-mutated tumours, regardless of the classifier used (Fig. 2d, supplementary Fig. 1, Online resource). Here, IDH1 is linked to neoplasm.